Aranesp

Pays: Union européenne

Langue: anglais

Source: EMA (European Medicines Agency)

Achète-le

Ingrédients actifs:

darbepoetin alfa

Disponible depuis:

Amgen Europe B.V.

Code ATC:

B03XA02

DCI (Dénomination commune internationale):

darbepoetin alfa

Groupe thérapeutique:

Other antianemic preparations

Domaine thérapeutique:

Anemia; Cancer; Kidney Failure, Chronic

indications thérapeutiques:

Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adults and paediatric patients.Treatment of symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy.

Descriptif du produit:

Revision: 45

Statut de autorisation:

Authorised

Date de l'autorisation:

2001-06-08

Notice patient

                                191
B. PACKAGE LEAFLET
192
PACKAGE LEAFLET: INFORMATION FOR THE USER
ARANESP 10 MICROGRAMS SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
ARANESP 15 MICROGRAMS SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
ARANESP 20 MICROGRAMS SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
ARANESP 30 MICROGRAMS SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
ARANESP 40 MICROGRAMS SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
ARANESP 50 MICROGRAMS SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
ARANESP 60 MICROGRAMS SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
ARANESP 80 MICROGRAMS SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
ARANESP 100 MICROGRAMS SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
ARANESP 130 MICROGRAMS SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
ARANESP 150 MICROGRAMS SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
ARANESP 300 MICROGRAMS SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
ARANESP 500 MICROGRAMS SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
darbepoetin alfa
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, pharmacist or
nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible
side effects not listed in this leaflet (see section 4).
WHAT IS IN THIS LEAFLET
1.
What Aranesp is and what it is used for
2.
What you need to know before you use Aranesp
3.
How to use Aranesp
4.
Possible side effects
5.
How to store Aranesp
6.
Contents of the pack and other information
7.
Instructions for injecting with the Aranesp pre-filled syringe
1.
WHAT ARANESP IS AND WHAT IT IS USED FOR
Your doctor has given you Aranesp (an anti-anaemic) to treat your
anaemia. Anaemia is when your
blood does not contain enough red blood cells and the symptoms may be
fatigue, weakness and
                                
                                Lire le document complet
                                
                            

Résumé des caractéristiques du produit

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Aranesp 10 micrograms solution for injection in pre-filled syringe.
Aranesp 15 micrograms solution for injection in pre-filled syringe.
Aranesp 20 micrograms solution for injection in pre-filled syringe.
Aranesp 30 micrograms solution for injection in pre-filled syringe.
Aranesp 40 micrograms solution for injection in pre-filled syringe.
Aranesp 50 micrograms solution for injection in pre-filled syringe.
Aranesp 60 micrograms solution for injection in pre-filled syringe.
Aranesp 80 micrograms solution for injection in pre-filled syringe.
Aranesp 100 micrograms solution for injection in pre-filled syringe.
Aranesp 130 micrograms solution for injection in pre-filled syringe.
Aranesp 150 micrograms solution for injection in pre-filled syringe.
Aranesp 300 micrograms solution for injection in pre-filled syringe.
Aranesp 500 micrograms solution for injection in pre-filled syringe.
Aranesp 10 micrograms solution for injection in pre-filled pen.
Aranesp 15 micrograms solution for injection in pre-filled pen.
Aranesp 20 micrograms solution for injection in pre-filled pen.
Aranesp 30 micrograms solution for injection in pre-filled pen.
Aranesp 40 micrograms solution for injection in pre-filled pen.
Aranesp 50 micrograms solution for injection in pre-filled pen.
Aranesp 60 micrograms solution for injection in pre-filled pen.
Aranesp 80 micrograms solution for injection in pre-filled pen.
Aranesp 100 micrograms solution for injection in pre-filled pen.
Aranesp 130 micrograms solution for injection in pre-filled pen.
Aranesp 150 micrograms solution for injection in pre-filled pen.
Aranesp 300 micrograms solution for injection in pre-filled pen.
Aranesp 500 micrograms solution for injection in pre-filled pen.
Aranesp 25 micrograms solution for injection in vial.
Aranesp 40 micrograms solution for injection in vial.
Aranesp 60 micrograms solution for injection in vial.
Aranesp 100 micrograms solution for injection in vial.
Aranesp 200 micrograms so
                                
                                Lire le document complet
                                
                            

Documents dans d'autres langues

Notice patient Notice patient bulgare 11-11-2022
Rapport public d'évaluation Rapport public d'évaluation bulgare 14-05-2019
Notice patient Notice patient espagnol 11-11-2022
Rapport public d'évaluation Rapport public d'évaluation espagnol 14-05-2019
Notice patient Notice patient tchèque 11-11-2022
Rapport public d'évaluation Rapport public d'évaluation tchèque 14-05-2019
Notice patient Notice patient danois 11-11-2022
Rapport public d'évaluation Rapport public d'évaluation danois 14-05-2019
Notice patient Notice patient allemand 11-11-2022
Rapport public d'évaluation Rapport public d'évaluation allemand 14-05-2019
Notice patient Notice patient estonien 11-11-2022
Rapport public d'évaluation Rapport public d'évaluation estonien 14-05-2019
Notice patient Notice patient grec 11-11-2022
Notice patient Notice patient français 11-11-2022
Rapport public d'évaluation Rapport public d'évaluation français 14-05-2019
Notice patient Notice patient italien 11-11-2022
Rapport public d'évaluation Rapport public d'évaluation italien 14-05-2019
Notice patient Notice patient letton 11-11-2022
Rapport public d'évaluation Rapport public d'évaluation letton 14-05-2019
Notice patient Notice patient lituanien 11-11-2022
Rapport public d'évaluation Rapport public d'évaluation lituanien 14-05-2019
Notice patient Notice patient hongrois 11-11-2022
Rapport public d'évaluation Rapport public d'évaluation hongrois 14-05-2019
Notice patient Notice patient maltais 11-11-2022
Rapport public d'évaluation Rapport public d'évaluation maltais 14-05-2019
Notice patient Notice patient néerlandais 11-11-2022
Rapport public d'évaluation Rapport public d'évaluation néerlandais 14-05-2019
Notice patient Notice patient polonais 11-11-2022
Rapport public d'évaluation Rapport public d'évaluation polonais 14-05-2019
Notice patient Notice patient portugais 11-11-2022
Rapport public d'évaluation Rapport public d'évaluation portugais 14-05-2019
Notice patient Notice patient roumain 11-11-2022
Rapport public d'évaluation Rapport public d'évaluation roumain 14-05-2019
Notice patient Notice patient slovaque 11-11-2022
Rapport public d'évaluation Rapport public d'évaluation slovaque 14-05-2019
Notice patient Notice patient slovène 11-11-2022
Rapport public d'évaluation Rapport public d'évaluation slovène 14-05-2019
Notice patient Notice patient finnois 11-11-2022
Rapport public d'évaluation Rapport public d'évaluation finnois 14-05-2019
Notice patient Notice patient suédois 11-11-2022
Rapport public d'évaluation Rapport public d'évaluation suédois 14-05-2019
Notice patient Notice patient norvégien 11-11-2022
Notice patient Notice patient islandais 11-11-2022
Notice patient Notice patient croate 11-11-2022
Rapport public d'évaluation Rapport public d'évaluation croate 14-05-2019

Rechercher des alertes liées à ce produit

Afficher l'historique des documents